The Latest

  • A woman talking to a doctor via a video chat on her smartphone using the Amwell platform.
    Image attribution tooltip
    Permission granted by Amwell
    Image attribution tooltip

    Amwell mulls divestitures

    The company is considering selling assets that could be more easily separated from the rest of the business without creating challenges for customers, executives said on a third quarter earnings call. 

  • Bankruptcy court
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Prospect clashes with Rhode Island regulators over plans to close two hospitals

    Prospect Medical Holdings is seeking approval from a bankruptcy court to close its hospitals in Rhode Island. Regulators and the new buyer say Prospect needs to follow through with a deal to sell them.

  • The exterior of the UnitedHealthcare office building with a large sign in the foreground that reads 'UnitedHealthcare, 7440 Woodland Drive'.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    UnitedHealthcare pays Optum doctors more than other doctors: study

    Researchers said the results suggest UnitedHealth may be sidestepping government rules meant to keep a lid on exorbitant payer profits. UnitedHealth said the study was “flat-out wrong.”

  • CMS Administrator Dr. Mehmet Oz speaks at an Aspen Institute event.
    Image attribution tooltip
    Permission granted by Aspen Institute
    Image attribution tooltip

    Legislators object to proposed CMS payment changes for diabetes tech

    In a letter to CMS Administrator Dr. Mehmet Oz, diabetes caucus leaders raised concerns that the agency’s proposals will reduce access to glucose monitors and insulin pumps.

  • Laptop, stethoscope and doctor writing in notebook for research planning or medical tech innovation in hospital office.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Health system execs are prioritizing AI, digital tech to overhaul care delivery: survey

    Leaders are worried some of the sector’s persistent challenges — like finance pressures and worker burnout — could worsen over the next five years without significant changes, according to a survey by Chartis.

  • A calculator and stethoscope rest on a medical bill.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Federal ACA enrollment kicks off without action on subsidies

    Millions of Americans are facing steep price hikes for Affordable Care Act coverage while Congress dithers over the issue. Experts say there’s not as much time to act as legislators may believe.

  • A sign notes that the U.S. Capitol Visitor Center is closed due to the government shutdown, with the capitol building in the background.
    Image attribution tooltip
    Al Drago via Getty Images
    Image attribution tooltip

    Health groups urge passage of bill to ease Medicare pay cuts for tests

    More than 30 organizations, including AdvaMed and the American Clinical Laboratory Association, are pushing for a permanent legislative solution to stop looming Medicare payment cuts for diagnostic tests.

  • The HHS in DC
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Medicare finalizes controversial cut to specialty care next year

    The CMS finalized the Medicare physician fee schedule for 2026 on Friday, one day before the statutory deadline. It includes an overall payment hike and a few policies that are deeply unpopular with specialists.

    Updated Nov. 4, 2025
  • two people shaking hands
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    CHS inks deal to sell stake in Tennessee hospital to VUMC

    The $600 million deal was foreshadowed during the company’s third quarter earnings call this month, when CEO Kevin Hammons said more hospital sales were in the works.

  • Medicine pill on 100 dollar banknote background
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    HRSA approves 340B rebate models to hospitals’ chagrin

    Drugs that will be subject to rebates in 340B next year include Bristol Myers Squibb’s Eliquis, Johnson & Johnson’s Stelara and Novo Nordisk’s Novolog.

  • Close up of a father and daughter having a video call with their doctor.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Few health systems report significant ROI from virtual care: survey

    Fewer than 30% of health system leaders said they earned a significant return on investment from virtual care offerings, according to the report by Sage Growth Partners.

  • Various pill bottles stand arranged on a pharmacy shelf.
    Image attribution tooltip
    IPGGutenbergUKLtd via Getty Images
    Image attribution tooltip
    Opinion

    New CBO report confirms 340B’s ballooning costs. Congress must act.

    Former Congressional Budget Office Director Dan Crippen argues the 340B discount program is overdue for reform.

  • A commercial structure featuring a brick and glass façade displays a  Cigna logo at the top of the building.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    Cigna’s 2026 pharmacy profits could be dampened by transition to rebate-free model

    Overall, Cigna expects earnings to grow next year after posting a solid third quarter. But investments in a new PBM model and discounted contracts for some big clients could lower Express Scripts’ profitability, executives said.

  • Exterior view of Summa Health's hospital in Akron, that says "Dr. Gary B. and Pamela S. Williams Tower" on the front.
    Image attribution tooltip
    Courtesy of Summa Health
    Image attribution tooltip

    Summa Health CEO to step down at end of 2025

    Dr. Cliff Deveny announced the transition less than a month after General Catalyst finalized its $515 million acquisition of Summa. 

  • Teladoc member and child using video service
    Image attribution tooltip
    Courtesy of Teladoc
    Image attribution tooltip

    Teladoc expands insurance coverage at mental health unit BetterHelp

    Executives expect insurance coverage availability will be “largely national” by the end of 2026. The initiative is important for Teladoc to turn around financial performance for the segment, which has seen earnings and revenue decline.

  • CVS pharmacy sign outside of Miami, Florida on Feb. 7, 2024
    Image attribution tooltip
    Joe Raedle via Getty Images
    Image attribution tooltip

    CVS hikes 2025 guidance despite goodwill impairment charge on healthcare delivery

    The healthcare giant beat Wall Street expectations in the third quarter, but reported a net loss after recording a $5.7 billion charge linked primarily to decelerating clinic growth at Oak Street Health.

  • Two people shake hands in a stock photo.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Tenet pledges more money for high-acuity growth in 2025

    The hospital operator will invest more in organic hospital growth and high-acuity service lines as it sees strong demand for services.

  • A modern office building facade with blue-tinted windows and a curved design. A sign near the roof reads “Centene Corporation” in blue and gray lettering.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    Centene posts $6.6B loss on massive value writedown

    The goodwill impairment charge is meant to realign Centene’s value on its own books with its value in the market, which has plummeted this year. Still, Centene upped its earnings outlook for 2025.

  • man in a dark blue suit speaks in the oval office
    Image attribution tooltip
    Anna Moneymaker via Getty Images
    Image attribution tooltip

    FDA, aiming to lower drug costs, moves to speed approval of biosimilars

    The agency will no longer require studies comparing copycat biologics to their branded counterparts, which could help developers bring them to market more quickly and cheaply. 

  • UnitedHealth Group office
    Image attribution tooltip
    Courtesy of UnitedHealth Group
    Image attribution tooltip

    UnitedHealth maps path back to Wall Street’s good graces

    The healthcare giant beat Wall Street expectations in the third quarter and raised its 2025 earnings guidance, albeit modestly.

  • financing medical debt fintechs
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Voters blame insurers for medical debt: poll

    More than 60% of respondents said insurance companies are most at fault for medical debt, compared with just 9% who blamed hospitals, according to a survey by nonprofit Undue Medical Debt.

  • Two people shake hands.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    UHS raises revenue guidance for 2025

    The operator increased its outlook after posting earnings growth in the third quarter, aided by strong demand for services in its acute business and a newly approved Medicaid state supplemental payment program.

  • A stethoscope rests on a medical insurance claim form.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    National payers OK on price transparency compliance: Turquoise Health

    The company has started to score insurers on their success in making rate data available online. Large payers tend to do better than their smaller peers.

  • People walking past the AI Zone at HLTH 2025.
    Image attribution tooltip
    Emily Olsen/Healthcare Dive
    Image attribution tooltip
    Deep Dive // HLTH25

    Health systems are racing to adopt AI. But can they prove its value?

    Measuring financial returns from AI can be challenging, experts said at the HLTH conference last week. But other metrics, like provider and patient satisfaction, are important too — and also impact providers’ bottom lines.

  • An image of an Express Scripts prescription bottle.
    Image attribution tooltip
    Courtesy of Express Scripts
    Image attribution tooltip

    Cigna’s Express Scripts to transition away from rebate drug model

    The massive PBM also said it will move to a cost-plus reimbursement model for in-network pharmacies. The moves come as the controversial drug middlemen attempt to lessen regulatory scrutiny.